Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
52
¥ million (amount of operating loss expansion)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsSecond quarter (interim period) of the fiscal year ending September 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥240 million0.0%
Operating profit¥-186 million
Ordinary income¥-190 million
Net income¥-192 million
Selling, general and administrative expenses¥352 million
Full-year earnings forecast
Net Sales
¥1,035 million
Operating profit
¥-356 million
Ordinary income
¥175 million
Net income for the current fiscal year
¥146 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
In line with planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Selling, general and administrative expenses¥52 million
- Increase in R&D expenses¥30 million
- Increase in personnel expenses¥11 million
- YoY difference in Stage 2 net sales¥68 million
- YoY difference in Stage 3 net sales¥-68 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- The earnings forecast includes only private-sector projects that have already been contracted or are equivalent to contracted projects.
- Because acceptance inspections are conducted for activities completed as of the end of March each year, revenue is recognized in the third or fourth quarter.
New initiatives
- License agreement with 株式会社シンアート for NMN-producing strains and production process technology
- R&D agreement with 森空バイオリファイナリー合同会社 for the commercialization of bioethanol derived from domestic timber
- Launch of collaboration on biomanufacturing using metabolomics
Key KPIsA metric the company considers important as a management benchmark.
- Biofoundry business fermentation capacity3,000 Up to L
- Target for development and commercialization of bioproducts16 Products or more
- 2030 production capacity for ethanol derived from woody biomassTens of thousands
- Pilot plant production capacity1,000 kL or more/year
- Productivity improvement in the biofoundry business3 times
Segment results
- Stage 2 (development stage)Net Sales¥240 millionYear on year against the same period last yearYoY difference: +¥0 million
- Stage 3 (commercialization stage)Net Sales¥0 millionYear on year against the same period last yearYoY difference: -¥68 million
Number of employees
Number of Employees50 People
Change during the periodGE Research Institute: 26 people (+4 people from the previous fiscal year); Biofoundry Research Institute: 11 people (unchanged from the previous fiscal year)
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending September 2026 |
| Net Sales | ¥240 million (YoY 0.0%) |
| Operating profit | ¥-186 million |
| Ordinary income | ¥-190 million |
| Net income | ¥-192 million |
| Selling, general and administrative expenses | ¥352 million |
| Full-year earnings forecast | Net Sales ¥1,035 million / Operating profit ¥-356 million / Ordinary income ¥175 million / Net income for the current fiscal year ¥146 million |
| Self-assessment against the plan | In line with plan |
| Segment results | Segment Stage 2 (development stage) / Net Sales ¥240 million / Year on year against the same period last year YoY difference: +¥0 million, Segment Stage 3 (commercialization stage) / Net Sales ¥0 million / Year on year against the same period last year YoY difference: -¥68 million |
| Breakdown of Factors Affecting the Change | Factors Selling, general and administrative expenses / Amount ¥52 million, Factors Increase in R&D expenses / Amount ¥30 million, Factors Increase in personnel expenses / Amount ¥11 million, Factors YoY difference in Stage 2 net sales / Amount ¥68 million, Factors YoY difference in Stage 3 net sales / Amount ¥-68 million |
| Key KPIs | Indicator name Biofoundry business fermentation capacity / Value 3,000 Up to L, Indicator name Target for development and commercialization of bioproducts / Value 16 Products or more, Indicator name 2030 production capacity for ethanol derived from woody biomass / Value Tens of thousands, Indicator name Pilot plant production capacity / Value 1,000 kL or more/year, Indicator name Productivity improvement in the biofoundry business / Value 3 times |
| Number of employees | Number of Employees 50 People / Change during the period GE Research Institute: 26 people (+4 people from the previous fiscal year); Biofoundry Research Institute: 11 people (unchanged from the previous fiscal year) |
| Assumptions Underlying the Business Outlook | The earnings forecast includes only private-sector projects that have already been contracted or are equivalent to contracted projects., Because acceptance inspections are conducted for activities completed as of the end of March each year, revenue is recognized in the third or fourth quarter. |
| New initiatives | License agreement with 株式会社シンアート for NMN-producing strains and production process technology, R&D agreement with 森空バイオリファイナリー合同会社 for the commercialization of bioethanol derived from domestic timber, Launch of collaboration on biomanufacturing using metabolomics |
Items this document does not state (16)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.SG&A expenses increased by ¥52 million from the same period of the previous year, including increases of ¥30 million in R&D expenses and ¥11 million in personnel expenses. The company explained that it recognized revenue as pipeline projects, including those related to ethanol derived from woody biomass, progressed, and incurred SG&A expenses as planned.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.